Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Intrinsic Value
Suven Pharmaceuticals Ltd. manufactures chemical products. [ Read More ]
The intrinsic value of one
SUVENPHAR
stock under the Base Case scenario is
330.92
INR.
Compared to the current market price of 643.9 INR,
Suven Pharmaceuticals Ltd
is
Overvalued by 49%.
Suven Pharmaceuticals Ltd's market capitalization is 163.9B INR.
SUVENPHAR stock price is 643.9 INR.
SUVENPHAR stock (330.92 INR) is 49% less than its price (643.9 INR).
SUVENPHAR stock (211.54 INR) is 67% less than its price (643.9 INR). Open DCF Valuation
SUVENPHAR stock (450.3 INR) is 30% less than its price (643.9 INR). Open Relative Valuation
SUVENPHAR has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
SUVENPHAR's ROIC (Return on Invested Capital) has decreased in the last 3 years from 26% to 25%.
SUVENPHAR's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
SUVENPHAR's Revenue has been growing by 8% per year for the last 3 years.
SUVENPHAR's Revenue has dropped by 13% over the past 12 months.
SUVENPHAR's ROE (Return on Equity) for the past 12 months is positive and is equal to 22%.
SUVENPHAR's ROE (Return on Equity) has decreased in the last 3 years from 31% to 22%.
SUVENPHAR's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 25%.
SUVENPHAR has positive Free Cash Flow for the last twelve months.
SUVENPHAR has positive Net Income for the last twelve months.
SUVENPHAR has very high three-year average ROIC (Return on Invested Capital): 26%. The company is very efficient at using invested capital to generate operating income.
SUVENPHAR has very high three-year average ROE (Return on Equity): 27%. The company is very efficient at transforming stockholders' equity into net income.
SUVENPHAR has positive Operating Income for the last twelve months.
SUVENPHAR has positive Gross Profit for the last twelve months.
SUVENPHAR's D/E (Debt to Equity) is very low and is equal to 0.
SUVENPHAR's short-term assets (12B INR) exceed its short-term liabilties (1B INR).
SUVENPHAR's long-term assets (21B INR) exceed its long-term liabilties (2B INR).
SUVENPHAR has negative Net Debt. This means that the company has more cash and short-term investments (7B INR) than debt (9m INR).
SUVENPHAR's Altman Z-Score is very high and is equal to 61.33.
SUVENPHAR earns more than enough operating income (5B INR) to safely cover interest payments on its debt (53m INR).
Valuation Backtest
Suven Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
SUVENPHAR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Suven Pharmaceuticals Ltd
Balance Sheet Decomposition
Suven Pharmaceuticals Ltd
| Current Assets | 11.7B |
| Cash & Short-Term Investments | 7.1B |
| Receivables | 1.4B |
| Other Current Assets | 3.2B |
| Non-Current Assets | 9.5B |
| Long-Term Investments | 1.2B |
| PP&E | 7.6B |
| Intangibles | 620.2m |
| Other Non-Current Assets | 35.2m |
| Current Liabilities | 1.1B |
| Accounts Payable | 425.9m |
| Other Current Liabilities | 697.8m |
| Non-Current Liabilities | 719.9m |
| Long-Term Debt | 8.7m |
| Other Non-Current Liabilities | 711.2m |
Earnings Waterfall
Suven Pharmaceuticals Ltd
|
Revenue
|
11.7B
INR
|
|
Cost of Revenue
|
-4.8B
INR
|
|
Gross Profit
|
6.9B
INR
|
|
Operating Expenses
|
-2.4B
INR
|
|
Operating Income
|
4.5B
INR
|
|
Other Expenses
|
-791.3m
INR
|
|
Net Income
|
3.7B
INR
|
Free Cash Flow Analysis
Suven Pharmaceuticals Ltd
SUVENPHAR Profitability Score
Profitability Due Diligence
Suven Pharmaceuticals Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Suven Pharmaceuticals Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
SUVENPHAR Solvency Score
Solvency Due Diligence
Suven Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Suven Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUVENPHAR Price Targets Summary
Suven Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
SUVENPHAR
is 816 INR
with a low forecast of 808 INR and a high forecast of 840 INR.
Shareholder Return
SUVENPHAR Price
Suven Pharmaceuticals Ltd
| Average Annual Return | 60.91% |
| Standard Deviation of Annual Returns | 98.54% |
| Max Drawdown | -43% |
| Market Capitalization | 163.9B INR |
| Shares Outstanding | 254 564 956 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Suven Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
Contact
IPO
Employees
Officers
The intrinsic value of one
SUVENPHAR
stock under the Base Case scenario is
330.92
INR.
Compared to the current market price of 643.9 INR,
Suven Pharmaceuticals Ltd
is
Overvalued by 49%.
You don't have any saved screeners yet
